TLP Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

TLP Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-57	Closed	-$5K	–	313
2017 Q1	$5K	Buy	+57	New	+$5.07K	﹤0.01%	284

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TLP Group's BMRN Position: Q2 2017 in Review

TLP Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 57 shares — an estimated $5K sold.

TLP Group first reported a position in BMRN in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

TLP Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
TLP Group sold 57 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $5K.
TLP Group first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 1 quarter.
TLP Group's BioMarin Pharmaceuticals position peaked at $5K in Q1 2017.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on TLP Group's 13F filing for Q2 2017, filed 11 Aug 2017.